Personalis prelim Q4 revenue $16.7M; FY2022 $65M, above guidance of $63-64M

Personalis, Inc.

2022-FY EPS reported -$2.48 revenue$65,047,000

FY2022 revenue from biopharma and other customers grew 42% YoY to $56.6M.
VA MVP revenue fell 82% to $8.4M for FY2022; remaining unfulfilled orders ~$9.1M.
Preliminary cash and equivalents totaled $167M as of Dec 31, 2022.
Management plans to extend cash runway while focusing on key product opportunities.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Personalis, Inc. reported fiscal year ended December 31, 2022 results: revenue $65.0 million. Guidance raised.

Period: fiscal year ended December 31, 2022
Revenue: $65.0 million
Guidance: raised
Result: preliminary results

Exact text from the filing

Personalis estimates revenue of approximately $16.7 million for the fourth quarter of 2022 and approximately $65.0 million for the full year of 2022, which exceeds the company’s previous full year guidance range of $63.0 to $64.0 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Personalis, Inc. reported fourth quarter ended December 31, 2022 results: revenue $16.7 million.

Period: fourth quarter ended December 31, 2022
Revenue: $16.7 million
Result: preliminary results

Exact text from the filing

Personalis estimates revenue of approximately $16.7 million for the fourth quarter of 2022 and approximately $65.0 million for the full year of 2022, which exceeds the company’s previous full year guidance range of $63.0 to $64.0 million.

View on SEC.gov

Browse all earnings releases →

Personalis, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-000121

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.